UY39979A - Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas - Google Patents
Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismasInfo
- Publication number
- UY39979A UY39979A UY0001039979A UY39979A UY39979A UY 39979 A UY39979 A UY 39979A UY 0001039979 A UY0001039979 A UY 0001039979A UY 39979 A UY39979 A UY 39979A UY 39979 A UY39979 A UY 39979A
- Authority
- UY
- Uruguay
- Prior art keywords
- pyrrolo
- triazines
- preparation
- treatment
- triazine compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254733P | 2021-10-12 | 2021-10-12 | |
| US202263347757P | 2022-06-01 | 2022-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39979A true UY39979A (es) | 2023-04-14 |
Family
ID=84330173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039979A UY39979A (es) | 2021-10-12 | 2022-10-12 | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12134625B2 (enExample) |
| EP (1) | EP4415816B1 (enExample) |
| JP (1) | JP2024539620A (enExample) |
| KR (1) | KR20240089275A (enExample) |
| AU (1) | AU2022367222A1 (enExample) |
| CA (1) | CA3234831A1 (enExample) |
| IL (1) | IL312157A (enExample) |
| MX (1) | MX2024004552A (enExample) |
| PY (1) | PY2289204A (enExample) |
| TW (1) | TW202322800A (enExample) |
| UY (1) | UY39979A (enExample) |
| WO (1) | WO2023064366A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508323A (ja) * | 2022-01-25 | 2025-03-26 | キネート バイオファーマ インク． | Ｃｄｋ４／６キナーゼの阻害薬 |
| JP2025538866A (ja) * | 2022-11-03 | 2025-12-02 | バイオスプライス セラピューティクス インコーポレイテッド | ４－アミノピロロ［２，１－ｆ］［１，２，４］トリアジンと、その調製物及び使用 |
| WO2024211797A1 (en) * | 2023-04-07 | 2024-10-10 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| CN119019402A (zh) * | 2023-05-24 | 2024-11-26 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 |
| IL326145A (en) * | 2023-07-26 | 2026-03-01 | Khora Spv 1 Llc | CDK2/4/6 kinase inhibitors |
| US20250206746A1 (en) * | 2023-12-22 | 2025-06-26 | Biosplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| US7507826B2 (en) | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| WO2006079055A2 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| JP2018526452A (ja) * | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Ｄｙｒｋ１ａの小分子抑制剤およびその使用 |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| WO2019074962A1 (en) * | 2017-10-10 | 2019-04-18 | Syros Pharmaceuticals, Inc. | PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES |
| JP7487170B2 (ja) | 2018-03-01 | 2024-05-20 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | 毒性小胞体ストレスを抑制するための化合物、組成物および方法 |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2020006115A1 (en) | 2018-06-26 | 2020-01-02 | Betty Tam | Methods of treating cancer using a clk inhibitor |
| AU2019362849B2 (en) | 2018-10-16 | 2025-06-05 | Dana-Farber Cancer Institute, Inc. | Azaindole inhibitors of wild-type and mutant forms of LRRK2 |
| WO2020150552A2 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| KR20230079003A (ko) | 2020-07-20 | 2023-06-05 | 니도 바이오사이언시스, 인코포레이티드 | 안드로겐 수용체 조절제로서의 인돌 화합물 |
| CA3234937A1 (en) | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors |
| EP4415817A1 (en) | 2021-10-12 | 2024-08-21 | BioSplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| JP2025525391A (ja) | 2022-06-23 | 2025-08-05 | バイオスプライス セラピューティクス インコーポレイテッド | ４－アルコキシピロロ［２，１－ｆ］［１，２，４］トリアジンならびにその製剤及び使用 |
-
2022
- 2022-10-12 UY UY0001039979A patent/UY39979A/es unknown
- 2022-10-12 PY PY202202289204A patent/PY2289204A/es unknown
- 2022-10-12 CA CA3234831A patent/CA3234831A1/en active Pending
- 2022-10-12 MX MX2024004552A patent/MX2024004552A/es unknown
- 2022-10-12 IL IL312157A patent/IL312157A/en unknown
- 2022-10-12 TW TW111138697A patent/TW202322800A/zh unknown
- 2022-10-12 AU AU2022367222A patent/AU2022367222A1/en active Pending
- 2022-10-12 JP JP2024522052A patent/JP2024539620A/ja active Pending
- 2022-10-12 US US17/964,489 patent/US12134625B2/en active Active
- 2022-10-12 EP EP22801289.4A patent/EP4415816B1/en active Active
- 2022-10-12 WO PCT/US2022/046416 patent/WO2023064366A1/en not_active Ceased
- 2022-10-12 KR KR1020247014718A patent/KR20240089275A/ko active Pending
-
2024
- 2024-08-15 US US18/806,231 patent/US20250171466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024539620A (ja) | 2024-10-29 |
| US20250171466A1 (en) | 2025-05-29 |
| IL312157A (en) | 2024-06-01 |
| US12134625B2 (en) | 2024-11-05 |
| EP4415816B1 (en) | 2026-03-18 |
| US20230312605A1 (en) | 2023-10-05 |
| MX2024004552A (es) | 2024-06-04 |
| TW202322800A (zh) | 2023-06-16 |
| CA3234831A1 (en) | 2023-04-20 |
| PY2289204A (es) | 2023-12-05 |
| AU2022367222A1 (en) | 2024-05-02 |
| WO2023064366A1 (en) | 2023-04-20 |
| EP4415816A1 (en) | 2024-08-21 |
| KR20240089275A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY2289204A (es) | Pirrolo [2,1-f] [1,2,4] triazinas y preparación y usos de las mismas | |
| UY39978A (es) | 7h-pirrolo[2,3-d]pirimidinas y preparación y usos de las mismas | |
| UY28084A1 (es) | Derivados antivirales de nucleosidos | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| BR112017018022A2 (pt) | "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| CR20220491A (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| MX2024015663A (es) | 4-alcoxipirrolo[2,1-f][1,2,4]triazinas y preparación y uso de las mismas | |
| US7495006B2 (en) | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | |
| SA98190487B1 (ar) | مركبات ثلاثي 3.2.1- ازولو ]4،5- D [ بيريميدين1,2,3-triazolo[4,5-D] pyrimidines حديثه واستخداماتها كعقاقير وطرق لتحضيرها | |
| BR9812048A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia | |
| NI200500090A (es) | Compuestos de benzofurano, composiciones y metodos para tratamiento y profilafixis de infecciones virales de hepatitis c y enfermedades asociadas | |
| CO6300934A2 (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas | |
| BR0213539A (pt) | Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| BR0312398A (pt) | Derivado de 1,3-difenilprop-2-en-1-ona substituìdo, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituìdo | |
| ES2087639T3 (es) | Nucleosidos terapeuticos. | |
| CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| MX2025005198A (es) | 4-aminopirrolo[2,1-f][1,2,4]triazinas y preparacion y usos de estas | |
| CL2021001209A1 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
| CO2022011183A2 (es) | Conjugados de proteínas-compuestos antivirales | |
| CO2025017454A2 (es) | Sales cristalinas o formas amorfas de 2-((1h-pirazol-3-il)metil)-6-((6-aminopiridin-2-il)metil)-4-metil-4,6-dihidro-5h-thiazolo[5',4':4,5]pirrolo[2,3-d]piridazin-5-ona |